NEOG Stock Analysis: Neogen | NASDAQ

Diagnostic Assays, Veterinary Instruments, Nutritional Supplements, Genetic Testing

Total Rating 54

Safety 77

Buy Signal 0.33

Medical Devices
Industry Rotation: +4.7

Market Cap: 2.54B
Avg Turnover: 54.3M

Risk 3d forecast

Volatility53.9%

VaR 5^th Pctl8.71%

VaR vs Median-1.64%

Reward TTM

Sharpe Ratio1.40

Rel. Str. IBD91.4

Rel. Str. Peer Group88.6 pctl

Character TTM

Beta1.742

Beta Downside1.995

Hurst Exponent0.440

Choppyness42.4%

Drawdowns 3y

Max DD78.79%

CAGR/Max DD-0.10

CAGR/Mean DD-0.17

EPS (Earnings per Share)

EPS CAGR: -17.21%
EPS Trend: -88.6%

Last SUE: 0.84
Qual. Beats: 0

Revenue

Rev. CAGR: -2.37%
Rev. Trend: -93.3%

Last SUE: 2.33
Qual. Beats: 5

Warnings

High Debt/EBITDA With Thin Interest Coverage

Interest Coverage Ratio Critical

Below Avwap Earnings

Tailwinds

Rs Leader

Seasonality 11.7 years of data

Jan -1.1% 17

Feb -2.5% 41

Mar +0.5% 2

Apr -4.8% 48

May +3.4% 32

Jun +7.8% 19

Jul +1.2% 20

Aug -0.9% 10

Sep -4.5% 28

Oct -4.1% 26

Nov +3.3% 39

Dec +2.2% 16

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: NEOG Neogen

Neogen Corporation (NEOG) is a U.S.-based provider of products and services focused on food and animal safety, operating through two main segments: Food Safety and Animal Safety. The Food Safety segment supplies diagnostic test kits and complementary reagents that detect pathogens, toxins, allergens, drug and pesticide residues, and other contaminants for food producers and processors. The Animal Safety segment offers veterinary instruments, drug delivery systems, nutritional supplements, parasiticides, vaccines, and rodent/insect control products marketed under multiple brands (Ideal, Prima Tech, Provecta, Ramik, Havoc, StandGuard, among others), serving livestock producers, ranchers, and veterinarians. The company also operates genomics labs providing DNA genotyping and trait analysis for livestock and companion animals, and offers software for managing and analyzing test results.

Founded in 1981 and headquartered in Lansing, Michigan, Neogen sells its products in the United States and internationally. Its customers operate in highly regulated industries where government food-safety mandates and veterinary health standards drive recurring demand for diagnostic testing and animal health products. The company is classified within the Health Care Supplies sub-industry of the Health Care sector.

Headlines to Watch Out For

Food Safety diagnostics demand grows on tightening global food safety regulations
Animal Safety margins pressured by integration costs and inventory write-downs
Elevated debt from 3M acquisition limits capital allocation flexibility

Piotroski VR-10 (Strict) 1.5

Net Income: -56.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA 1.60 > 1.0
NWC/Revenue: 48.98% < 20% (prev 42.60%; Δ 6.38% < -1%)
CFO/TA 0.03 > 3% & CFO 85.2m > Net Income -56.1m
Net Debt (621.7m) to EBITDA (105.1m): 5.91 < 3
Current Ratio: 3.90 > 1.5 & < 3
Outstanding Shares: last quarter (218.1m) vs 12m ago 0.49% < -2%
Gross Margin: 47.40% > 18% (prev 41.10%; Δ 6.30% > 0.5%)
Asset Turnover: 26.46% > 50% (prev 26.25%; Δ 0.21% > 0%)
Interest Coverage Ratio: -0.20 > 6 (EBIT TTM -11.2m / Interest Expense TTM 56.4m)

Altman Z'' 2.09

A: 0.13 (Total Current Assets 582.5m - Total Current Liabilities 149.5m) / Total Assets 3.30b
B: -0.17 (Retained Earnings -556.2m / Total Assets 3.30b)
C: -0.00 (EBIT TTM -11.2m / Avg Total Assets 3.34b)
D: 1.71 (Book Value of Equity 2.09b / Total Liabilities 1.22b)
Altman-Z'' = 2.09 = BBB

Beneish M -3.18

DSRI: 0.99 (Receivables 136.2m/138.5m, Revenue 884.0m/886.9m)
GMI: 0.87 (GM 41.10% / 47.40%)
AQI: 0.97 (AQ_t 0.72 / AQ_t-1 0.74)
SGI: 1.00 (Revenue 884.0m / 886.9m)
TATA: -0.04 (NI -56.1m - CFO 85.2m) / TA 3.30b)
Beneish M = -3.18 (Cap -4..+1) = AA

What is the price of NEOG shares?

As of October 22, 2026, the stock is trading at USD 11.79 with a total of 2,118,740 shares traded. Over the past week, the price has changed by -2.80%, over one month by -13.37%, over three months by +18.73% and over the past year by +99.83%.

Current recommended Stop Loss: 10.90 (which is 7.5% or 1.5 ATR below the current price).

Is NEOG a buy, sell or hold?

Neogen has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy NEOG.

StrongBuy: 1
Buy: 2
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the NEOG price?

Analysts Target Price	14	18.7%

Neogen (NEOG) - Fundamental Data Overview as of 21 October 2026

Market Cap USD = 2.54b (2.54b USD * 1.0 USD.USD)
P/E Forward = 16.0
P/S = 2.8721
P/B = 1.4136
P/EG = 0.6575
Revenue TTM = 884.0m USD
EBIT TTM = -11.2m USD
EBITDA TTM = 105.1m USD
Long Term Debt = 793.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = unknown (none)
Debt = 793.7m USD (corrected: LT Debt 793.7m + ST Debt none)
Net Debt = 621.7m USD (calculated: Debt 793.7m - CCE 172.0m)
Enterprise Value = 3.16b USD (2.54b + Debt 793.7m - CCE 172.0m)
Interest Coverage Ratio = -0.20 (Ebit TTM -11.2m / Interest Expense TTM 56.4m)
EV/FCF = 63.53x (Enterprise Value 3.16b / FCF TTM 49.7m)
FCF Yield = 1.57% (FCF TTM 49.7m / Enterprise Value 3.16b)
FCF Margin = 5.63% (FCF TTM 49.7m / Revenue TTM 884.0m)
Net Margin = -6.35% (Net Income TTM -56.1m / Revenue TTM 884.0m)
Gross Margin = 47.40% ((Revenue TTM 884.0m - Cost of Revenue TTM 465.0m) / Revenue TTM)
Gross Margin QoQ = 47.35% (prev 47.85%)
Tobins Q-Ratio = 0.96 (Enterprise Value 3.16b / Total Assets 3.30b)
Interest Expense / Debt = 7.11% (Interest Expense 56.4m / Debt 793.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -8.86m (EBIT -11.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.90 (Total Current Assets 582.5m / Total Current Liabilities 149.5m)
Debt / Equity = 0.38 (Debt 793.7m / totalStockholderEquity, last quarter 2.09b)
Debt / EBITDA = 5.91 (Net Debt 621.7m / EBITDA 105.1m)
Debt / FCF = 12.50 (Net Debt 621.7m / FCF TTM 49.7m)
Total Stockholder Equity = 2.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.68% (Net Income -56.1m / Total Assets 3.30b)
RoE = -2.68% (Net Income TTM -56.1m / Total Stockholder Equity 2.10b)
RoCE = -0.39% (EBIT -11.2m / Capital Employed (Equity 2.10b + L.T.Debt 793.7m))
RoIC = -0.28% (negative operating profit) (NOPAT -8.86m / Invested Capital 3.11b)
WACC = 10.09% (E(2.54b)/V(3.33b) * Re(11.49%) + D(793.7m)/V(3.33b) * Rd(7.11%) * (1-Tc(0.21)))
Discount Rate = 11.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.89 | Cagr: 0.31%
[DCF] Terminal Value 69.58% ; FCFF base≈49.7m ; Y1≈50.0m ; Y5≈52.9m
[DCF] Fair Price = 0.06 (EV 634.9m - Net Debt 621.7m = Equity 13.2m / Shares 218.3m; r=10.09% [WACC]; 5y FCF grow 0.0% → 2.50% )
[DCF] Fair Price = 0.06 (out of range, set to none)
EPS Correlation: -88.56 | EPS CAGR: -17.21% | SUE: 0.84 | # QB: 0
Revenue Correlation: -93.30 | Revenue CAGR: -2.37% | SUE: 2.33 | # QB: 5
EPS current Quarter (2026-11-30): EPS=0.06 | Chg30d=-32.15% | Revisions=+0% | Analysts=3
EPS next Quarter (2027-02-28): EPS=0.08 | Chg30d=+13.64% | Revisions=+0% | Analysts=3
EPS current Year (2027-05-31): EPS=0.33 | Chg30d=+7.52% | Revisions=+0% | GrowthEPS=+4.2% | GrowthRev=+2.0%
EPS next Year (2028-05-31): EPS=0.45 | Chg30d=+4.65% | Revisions=-25% | GrowthEPS=+35.0% | GrowthRev=-6.8%
[Analyst] Revisions Ratio: -25% (up=0, down=1)